EFFECT OF CHOLECALCIFEROL ON PULSE WAVE VELOCITY IN WOMEN WITH ARTERIAL HYPERTENSION IN PREMENOPAUSAL AND EARLY POSTMENOPAUSAL PERIODS

Objective. The objective of our study was to compare the performance of vascular stiffness (VS) and the left ventricular (LV) remodeling process indicators in patients with arterial hypertension (AH) under renal replacement therapy (RRT), and patients with essential hypertension.Design and methods. 158 people were included in the study, divided into 4 comparable age groups: 32 patients receiving programmed hemodialysis (PH), 37 recipients of renal transplant (RT), 69 patients with essential AH and 20 healthy volunteers. All the patients underwent 24-hour blood pressure (BP) monitoring with an assessment of VS and central BP (SBPao) and echocardiography (EchoCG).Results. The patients under PH and after RT did not have any significant differences in the values of central and peripheral BP. Comparing the groups of patients under RRT with the group of essential AH, the office systolic (SBP) and diastolic (DBP) BP values did not differ significantly. Аlthough, at night, considerably higher DBP(n) and SBPao(n) values were detected in patients under RRT, and in the patients after RT SBP(n) and PP(n) values were also increased. An increase in the SBPao values of more than 10 m/sec was detected only in the groups of patients under RRT. In all the groups with hypertension all indicators of daily VS differed significantly from the group of healthy volunteers. PTIN (Pulse Time Index of Norm) in the studied groups had more evident differences: in the healthy volunteers it was in the range of 80-90%, in the patients with essential hypertension — 50-60%, and in the patients under PH and after RT — 20-40%. In all groups of patients with AH, the average the posterior wall thickness (PWT) of the LV and the interventricular septum thickness (IVST) were close to the upper limit of the norm. In the groups of patients with AH an increase in the relative wall thickness (RWT) of the LV was also detected. Furthermore, considerably higher the values of ILVmass, IVST were found in the group of patients on PH in comparison with the patients after RT. In addition, in all the groups of patients with AH, there was a tendency to LV spherification in comparison with the healthy volunteers, and in the group of essential AH the difference was more pronounced compared with the group under RRT.Conclusion. In the patients with arterial hypertension who undergo renal replacement therapy, higher average values of central BP, higher vascular stiffness (daily pulse wave velocity in the aorta and a longer period of pulse wave velocity increase in the aorta during the day (PTIN)) and less pronounced left ventricular spherification are recorded in comparison with the patients with essential hypertension while office BP values remained consistent.

Download Full-text

PULSE WAVE VELOCITY AT PATIENTS WITH ARTERIAL HYPERTENSION

Atherosclerosis Supplements ◽

10.1016/s1567-5688(08)70643-3 ◽

2008 ◽

Vol 9 (1) ◽

pp. 160

Author(s):

T. Chalabi ◽

U. Brel ◽

V. Tsoma ◽

G. Mazina ◽

S. Nedogoda

Keyword(s):

Pulse Wave Velocity ◽

Arterial Hypertension ◽

Wave Velocity ◽

Pulse Wave

Download Full-text

Influence of losartan vs amlodipin on pulse wave velocity in patients with mild to moderate arterial hypertension

American Journal of Hypertension ◽

10.1016/j.amjhyper.2005.03.047 ◽

2005 ◽

Vol 18 (5) ◽

pp. A19-A19

Author(s):

G RADCHENKO ◽

Y SIRENKO ◽

S KUSHNIR ◽

J KUDINA

Keyword(s):

Pulse Wave Velocity ◽

Arterial Hypertension ◽

Wave Velocity ◽

Pulse Wave

Download Full-text

Pulse Wave Velocity and Pulse Pressure in Patients With Arterial Hypertension

Kardiologiia ◽

10.18565/cardio.2014.5.34-38 ◽

2014 ◽

Vol 5_2014 ◽

pp. 34-38

Author(s):

O.A. Kislyak Kislyak ◽

A.V. Starodubova Starodubova ◽

Keyword(s):

Pulse Wave Velocity ◽

Arterial Hypertension ◽

Wave Velocity ◽

Pulse Pressure ◽

Pulse Wave

Download Full-text

P.022 COMPARISON OF COMPLIOR, SPHYGMOCOR AND ARTERIOGRAPH FOR ASSESSMENT OF AORTIC PULSE WAVE VELOCITY IN PATIENTS WITH ARTERIAL HYPERTENSION

Artery Research ◽

10.1016/j.artres.2007.07.079 ◽

2007 ◽

Vol 1 (2) ◽

pp. 57

Author(s):

M.W. Rajzer ◽

M. Klocek ◽

W. Wojciechowska ◽

I. Palka ◽

M. Brzozowska-Kiszka ◽

...

Keyword(s):

Pulse Wave Velocity ◽

Arterial Hypertension ◽

Wave Velocity ◽

Pulse Wave ◽

Aortic Pulse Wave Velocity

Download Full-text

PARAMETERS OF CENTRAL AORTIC PRESSURE, PULSE WAVE VELOCITY IN PATIENTS WITH ARTERIAL HYPERTENSION DURING THERAPY WITH TELMISARTAN

Siberian medical review ◽

10.20333/25000136-2015-1-47-51 ◽

2015 ◽

pp. 47-51

Author(s):

V. V. Gorbunov ◽

◽

E. N. Bryantseva ◽

Keyword(s):

Pulse Wave Velocity ◽

Arterial Hypertension ◽

Wave Velocity ◽

Pressure Pulse ◽

Pulse Wave ◽

Aortic Pressure ◽

Central Aortic Pressure ◽

Aortic Pressure Pulse

Download Full-text

The Influence of Non-Alc oholic Fatty Liver Disease on Indicators of Arterial Stiffness and Risk of Cardiovascular Complications in Patients with Arterial Hypertension

The Russian Archives of Internal Medicine ◽

10.20514/2226-6704-2020-10-4-296-304 ◽

2020 ◽

Vol 10 (4) ◽

pp. 296-304

Author(s):

M. E. Statsenko ◽

A. M. Streltsova ◽

M. I. Turovets

Keyword(s):

Liver Disease ◽

Pulse Wave Velocity ◽

Arterial Hypertension ◽

Fatty Liver ◽

Wave Velocity ◽

Fatty Liver Disease ◽

Pulse Wave ◽

Aortic Pressure ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Aim. To determine the value of concomitant non-alcoholic fatty liver disease in patients with arterial hypertension in the progression of rigidity of the main arteries and in increase of risk of cardiovascular complications. Material and methods. A cross-sectional comparative study was conducted. Group 1 (n=50, 35(70%) women, average age 57,4±6,9 years) included patients with arterial hypertension and non-alcoholic fatty liver disease, group 2 (n=50, 40(80%) women, average age 56,5±7,0 years) included patients with arterial hypertension only. The groups were comparable in the main clinical and demographic indicators (p>0,05). A comparative analysis of pulse wave velocity, central aortic pressure, vascular age and a 10-year risk of developing cardiovascular complications in both groups was performed.Results. There is a statistically larger number of patients with metabolic index>7,0 (58,0% vs 28,0%, p=0,0019). It was also established that systolic (121,9±10,9 mm Hg vs 115,9±8,9 mm Hg) and diastolic (82,5±9,3 mm Hg vs 77,4±8,9 mm Hg) aortic pressure, as well as the augmentation index (26,5±8,5% vs 18,6±4,2%), were significantly higher in patients with arterial hypertension and non-alcoholic fatty liver disease than in patients with isolated arterial hypertension. In the 1st group, a statistically significant increased pulse wave velocity was found both in muscular (12,0±3,1 m/s vs 10,6±1,8 m/s) and elastic (10,4±2,8 m/s vs 9,1±1,7 m/s) vessels, which indicates an increase in arterial stiffness. In addition, there was an increase in post-occlusal pulse wave velocity in this category of patients (11,0±3,3 m/s vs 9,4±1,9 m/s, p=0,0037). A significant increase in vascular age in relation to the passport age (60,4 [56,0:68,0] years vs 58,0 [53,0:60,0] years) and an increase in the 10-year fatal risk was detected (2,15 [1,42: 4,63] and 1,05 [0,52: 2,82] %, p = 0,0043 ) were also revealed in patients with arterial hypertension and non-alcoholic fatty liver disease compared to patients with isolated arterial hypertension. Significantly more patients with a high (13 (26,0%) vs 5 (10,0%), p = 0,0332) total cardiovascular risk were observed in group 1 than in group 2.Conclusions. Arterial stiffness was significantly higher in patients with arterial hypertension and non-alcoholic fatty liver disease than in patients with isolated arterial hypertension, which is confirmed by a statistically significant increase in pulse wave velocity and central aortic pressure. Comorbid patients have pronounced endothelial dysfunction, which is confirmed by a significant increase in the post-occlusion rate of the pulse wave. An increase in vascular age in relation to the passport age indicates earlier aging of blood vessels in the 1st group compared with the 2nd group. Patients in the main group have a higher incidence of a high 10-year risk of developing cardiovascular events compared with patients in the control group.

Download Full-text

The influence of antyhypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1-2 grades in international VICTORY clinical trial

Systemic Hypertension ◽

10.26442/2075-082x_2018.2.6-13 ◽

2018 ◽

Vol 15 (2) ◽

pp. 6-13 ◽

Cited By ~ 1

Author(s):

I E Chazova ◽

T V Martynyuk ◽

R Accetto ◽

Yu N Sirenko ◽

J Vincelj ◽

...

Keyword(s):

Clinical Trial ◽

Arterial Pressure ◽

Pulse Wave Velocity ◽

Arterial Hypertension ◽

Wave Velocity ◽

Pulse Wave ◽

Fixed Combination ◽

Randomized Clinical Study ◽

Study Results ◽

The Impact

Objective - to explore influence of valsartan monotherapy use and its use in combination with hydrochlorothiazide (HCTZ) on pulse-wave velocity (PWV) and central arterial pressure (CAP) in patients with arterial hypertension (AH) of 1-2 grades in international VICTORY clinical trial. Materials and methods. The international multicenter prospective randomized clinical study VICTORY that lasted for 16 weeks included patients with 1-2 grades AH. In patients who previously received antihypertensive therapy a 7 days washout period was carried out. All patients started their therapy with 80 mg valsartan (Valsacor®, KRKA, Slovenia); in Russia the starter dose of Valsacor®, KRKA was 160 mg in previously treated patients that did not influence the study results. If after 4 weeks of treatment BP was more than 140/90 mm hg (more than 130/80 mm hg in high risk patients or in diabetes mellitus patients) the dose of valsartan was increased to 160 mg (320 mg in Russia) or diuretic in fixed combination with valsartan was added (160 mg valsartan/12.5 mg HCTZ): Valsacor® H 160 (KRKA, Slovenia). If target BP after 8 weeks of treatment was not reached valsartan dose was increased to 320 mg or fixed combination of valsartan and diuretic (160 mg/12.5 mg) was used. If target BP after 12 weeks of treatment was not reached - valsartan and diuretic 320 mg/12.5 mg were used. PWV and CAP (SphygmoCor®, AtCorMedical) were assessed at baseline and after 16 weeks of treatment. The primary endpoints were assessment of the impact of studied medications on aortic stiffness, aortic augmentation index and comparison of absolute medians of reached central and peripheral BP reduction with baseline value. Results. Of 365 patients included in the study 74 were included in PWV and CAP study subgroup. Valsartan and its combination with HCTZ were effective in CBP reduction. The mean absolute reduction of central systolic and diastolic BP after 16 weeks of treatment was 19.7±12.9 mm hg and 13.9±8.5 mm hg, respectively (р

Download Full-text